Guanabana

1. What conditions has Guanabana been studied for?

• Cancer (primarily preclinical): Multiple studies focus on anticancer activity of Annona muricata (guanabana/graviola/soursop) extracts and constituents (notably acetogenins), including breast cancer models and cancer cell lines.

• Oxidative stress / antioxidant activity: Leaf preparations (infusions and ethanolic extracts) were assessed for antioxidant capacity (e.g., DPPH radical scavenging, iron-reducing power).

• Safety/tolerability and organ effects: A systematic review summarized reported effects including hepatoprotective and neurotoxic findings, plus antinociceptive and anti-ulcerative effects (largely from in vitro and animal studies).

• Food safety exposure context (not a health condition): One abstract describes pesticide residue testing methods applied to guanabana dried fruit among other fruits (analytical/quality control focus rather than clinical outcomes).

2. Does it work in treating those conditions? Summarize the evidence.

• Cancer: Evidence is suggestive but not definitive, and is mostly non-human.

  • Animal model (breast cancer): In a DMBA-induced breast cancer rat model, Annona muricata leaf essential oil given daily (50, 100, 200 mg/kg/day) reduced tumor frequency and reduced accumulated tumor volume by 50% (100 mg/kg) and 71% (200 mg/kg). It also increased GSH, decreased MDA, and lowered VEGF versus DMBA controls (e.g., VEGF decreased from 70.75 ± 7.15 pg/mL to 46.50 ± 9.00 and 34.13 ± 11.50 pg/mL at 100 and 200 mg/kg).

  • Cell culture (combination with chemotherapy): An aqueous infusion alone showed low cytotoxicity in both cancer and healthy cells at tested concentrations (125–250 µg/mL), but enhanced cytotoxic effects when combined with multiple first-line antineoplastic drugs in cancer cell lines while sparing healthy cells at those concentrations. This supports a potential “chemosensitizer/modulator” role, but it remains in vitro.

  • Reviews: Two review studies conclude there is “good evidence” for chemopreventive/therapeutic potential based on existing laboratory and preclinical literature, but they also emphasize the need for safety attention and further studies in people with cancer.

  • Human efficacy: The studies reviewed here do not report clear clinical trial outcomes demonstrating that guanabana treats cancer in humans.

• Antioxidant effects: Leaf infusions and ethanolic extracts contained phenolics (including quercetin) and showed measurable antioxidant activity in vitro. Infusions had higher DPPH inhibition (about 65–73% depending on region) than ethanolic extracts (about 45–50%). This supports antioxidant capacity in lab assays, but does not by itself prove clinical benefit.

• Other traditional/organ-protective effects: The systematic review reports hepatoprotective, antinociceptive, and anti-ulcerative effects in the literature, but the study does not provide specific human-confirmed therapeutic outcomes; much of the evidence appears preclinical.

3. What health benefits does it have?

• Antioxidant potential (in vitro): Leaf preparations contain alkaloids, flavonoids, tannins, and phenolic compounds, with quercetin identified as a major compound. Infusions showed stronger antioxidant capacity than ethanolic extracts in DPPH assays, and geographic variation affected levels (northern region higher in total flavonoids and iron-reducing power).

• Potential anticancer/chemopreventive activity (preclinical): Reviews and experimental studies suggest anticancer potential of extracts/constituents (including acetogenins). In an animal breast cancer model, leaf essential oil reduced tumor burden and improved oxidative stress markers (higher GSH, lower MDA) and lowered VEGF.

• Possible adjunct role with conventional therapy (in vitro): An aqueous infusion may potentiate cytotoxicity of standard antineoplastic drugs in cancer cells while sparing healthy cells at tested concentrations, suggesting a potential complementary “modulator” effect (not yet validated clinically).

• Other reported effects (mostly preclinical): The systematic review notes hepatoprotective, antinociceptive, and anti-ulcerative effects reported in the literature, but the strength and human relevance are not established from the study alone.

4. Does it have any downsides or side effects?

• Potential neurotoxicity signal (preclinical): The systematic review explicitly lists neurotoxic effects among reported findings for A. muricata and its acetogenins. This is an important caution, especially because acetogenins are bioactive and may have narrow safety margins.

• Translation uncertainty (animal-to-human dosing): The systematic review notes that doses and durations producing toxicity in animals may not directly translate to humans. This cuts both ways: it may overestimate or underestimate human risk.

• Overall tolerability assessment is not definitive: The systematic review concludes an overall “favourable safety and tolerability profile,” but this conclusion is based on a mixed body of in vitro, animal, and limited human evidence (as described in the study), so real-world safety—especially with long-term use, high doses, or concentrated extracts—remains uncertain.

• Contaminant/exposure considerations (food product context): One abstract highlights pesticide residue testing in dried guanabana fruit exports. While it does not report contamination levels in the excerpt provided, it underscores that agricultural residues can be a relevant safety variable depending on sourcing and quality control.

• Drug interaction potential (theoretical/early evidence): The in vitro combination study suggests guanabana infusion can enhance cytotoxic effects of antineoplastic drugs in cancer cells. If such modulation occurs in humans, it could be beneficial or could increase toxicity depending on context; clinical interaction data are not provided in the studies.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (e.g., effects by CYP450 genotype, transporter variants, or tumor genomics) for guanabana.

• Mechanistic clue (not pharmacogenomics): One study used in silico docking showing quercetin and hyperoside (metabolites in the infusion) interact with the A2B adenosine receptor, proposed as a mechanistic contributor to drug-modulating effects. However, it does not evaluate genetic variants in the receptor (ADORA2B) or differential responses by genotype.

• Practical implication: Because pharmacogenomic data are absent in these studies, no evidence-based claims can be made that guanabana is specifically beneficial or harmful for particular genetic variants. Any such claims would require dedicated human studies assessing genotype–response and genotype–toxicity relationships.

References

1. Comparative Analysis of Infusions and Ethanolic Extracts of
   Gustavo A Hernandez-Fuentes, Osiris G Delgado-Enciso, Edgar G Larios-Cedeño, Juan M Sánchez-Galindo, Silvia G Ceballos-Magaña, Kayim Pineda-Urbina, Mario A Alcalá-Pérez, Nancy E Magaña-Vergara, Josuel Delgado-Enciso, Uriel Díaz-Llerenas, Janet Diaz-Martinez, Idalia Garza-Veloz, Margarita L Martinez-Fierro, Iram P Rodriguez-Sanchez, Ivan Delgado-Enciso (2024) - Life (Basel, Switzerland)
2. The safety and tolerability of Annona muricata leaf extract: a systematic review.
   Wai-Jo Jocelin Chan, Andrew J McLachlan, Jane R Hanrahan, Joanna E Harnett (2020) - The Journal of pharmacy and pharmacology
3. Emerging therapeutic potential of graviola and its constituents in cancers.
   Asif Khurshid Qazi, Jawed A Siddiqui, Rahat Jahan, Sanjib Chaudhary, Larry A Walker, Zafar Sayed, Dwight T Jones, Surinder K Batra, Muzafar A Macha (2018) - Carcinogenesis
4. Phytochemical Constituents and Ameliorative Effect of the Essential Oil fromAnnona muricataL. Leaves in a Murine Model of Breast Cancer
   Juan Pedro Rojas-Armas, Jorge Luis Arroyo-Acevedo, Miriam Palomino-Pacheco, José Manuel Ortiz-Sánchez, James Calva (2022)
5. Determination of pesticides in dried minor tropical fruits from Colombia using the Quick, Easy, Cheap, Effective, Rugged, and Safe method-gas chromatography-tandem mass spectrometry.
   Diana Angélica Varela-Martínez, Miguel Ángel González-Curbelo, Javier González-Sálamo, Javier Hernández-Borges (2020) - Journal of separation science

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.